The retinitis pigmentosa treatment market features a dynamic competitive landscape driven by innovation, strategic partnerships, and emphasis on personalized medicine. For comprehensive competitive intelligence, refer to the Retinitis Pigmentosa Treatment Market report.

Major Industry Players

Novartis (CH) focuses on expanding research capabilities, particularly in gene therapy, aligning with increasing demand for targeted treatments. In August 2025, Novartis announced a strategic partnership with a leading biotechnology firm to co-develop a novel gene therapy for retinitis pigmentosa, leveraging both companies' expertise in genetic research.

Regeneron Pharmaceuticals (US) leverages its robust pipeline of biologics, indicating commitment to innovation. In September 2025, Regeneron unveiled a new clinical trial for its innovative biologic treatment targeting retinitis pigmentosa, combining gene editing with traditional pharmacological approaches.

Spark Therapeutics (US), known for pioneering work in gene therapy, continues solidifying market presence through strategic collaborations. In July 2025, Spark Therapeutics launched a patient assistance program to improve access to its gene therapy, reflecting growing recognition of patient-centric strategies.

Other Key Players

Roche (CH), Santen Pharmaceutical (JP), Astellas Pharma (JP), GenSight Biologics (FR), Bayer (DE), and Alkeus Pharmaceuticals (US) contribute to market diversity through various therapeutic approaches and regional strengths.

Competitive Dynamics

The market appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands.